Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry

医学 经皮冠状动脉介入治疗 阿司匹林 传统PCI 内科学 氯吡格雷 危险系数 人口 心脏病学 急性冠脉综合征 倾向得分匹配 置信区间 心肌梗塞 环境卫生
作者
Chunfeng Dai,Muyin Liu,Zheng Yang,Youran Li,You Zhou,Danbo Lu,Ying Xia,Ao Chen,Chenguang Li,Hao Lu,Yuxiang Dai,Jianying Ma,Zhangwei Chen,Juying Qian,Junbo Ge
出处
期刊:BMC Medicine [BioMed Central]
卷期号:22 (1) 被引量:3
标识
DOI:10.1186/s12916-024-03374-3
摘要

Abstract Background Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, the vast majority of patients with acute coronary syndrome (ACS) and aspirin intolerance were excluded. We aimed to explore this question in a real-world population. Methods Patients enrolled in the ASPIRATION registry were grouped according to the DAPT strategy that they received after PCI. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. Propensity score matching (PSM) was adopted for confounder adjustment. Results A total of 7135 patients were reviewed. After one-year follow-up, the indobufen group was associated with the same risk of MACCE versus the aspirin group after PSM (6.5% vs. 6.5%, hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.65 to 1.52, P = 0.978). However, BARC type 2, 3, or 5 bleeding was significantly reduced (3.0% vs. 11.9%, HR = 0.24, 95% CI = 0.15 to 0.40, P < 0.001). These results were generally consistent across different subgroups including aspirin intolerance, except that indobufen appeared to increase the risk of MACCE in patients with ACS. Conclusions Indobufen shared the same risk of MACCE but a lower risk of bleeding after PCI versus aspirin from a real-world perspective. Due to the observational nature of the current analysis, future studies are still warranted to further evaluate the efficacy of indobufen based DAPT, especially in patients with ACS. Trial registration Chinese Clinical Trial Register ( https://www.chictr.org.cn ); Number: ChiCTR2300067274.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
campus发布了新的文献求助10
1秒前
军帽发布了新的文献求助10
2秒前
是子子子子枫完成签到,获得积分10
2秒前
3秒前
苹果白凝发布了新的文献求助50
3秒前
麻烦~发布了新的文献求助10
4秒前
6秒前
传奇3应助岁岁采纳,获得10
8秒前
9秒前
11秒前
MJS完成签到,获得积分10
12秒前
屿若发布了新的文献求助10
12秒前
共享精神应助刘无敌采纳,获得10
12秒前
wtt发布了新的文献求助10
12秒前
CC关注了科研通微信公众号
13秒前
sn完成签到,获得积分10
15秒前
bkagyin应助飞翔的企鹅采纳,获得10
15秒前
15秒前
虞滢滢发布了新的文献求助10
15秒前
量子星尘发布了新的文献求助10
16秒前
麻烦~完成签到,获得积分10
16秒前
17秒前
Li chun sheng完成签到,获得积分10
19秒前
3366发布了新的文献求助10
20秒前
21秒前
CipherSage应助谨言采纳,获得10
22秒前
qqqqqqy完成签到,获得积分10
26秒前
BDMAXPK发布了新的文献求助10
27秒前
彭于晏应助Shrine采纳,获得10
29秒前
深情的皮皮虾完成签到 ,获得积分10
32秒前
i_jueloa完成签到,获得积分10
32秒前
33秒前
35秒前
35秒前
岁岁完成签到,获得积分10
37秒前
木乙发布了新的文献求助10
38秒前
39秒前
Tong完成签到,获得积分10
39秒前
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975658
求助须知:如何正确求助?哪些是违规求助? 3519986
关于积分的说明 11200481
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806376